New DFS Data from SunRISe 1 Cohort 4 for TAR 200 in HR NMIBC

Phase2b SunRISe-1 Cohort 4 results, presented at AUA 2025 and published online, show85.3% disease-free survival (DFS) at 6 months and 81.1% at 9 months for TAR‑200monotherapy in patients with papillary-only HR‑NMIBC. The study included 52patients, with bladder preservation in 94.2% of cases and tolerable low-gradeurinary adverse events. This dataset supports expanded confidence in TAR‑200’seffectiveness in broader NMIBC subtypes.

‍Citation: https://www.biospace.com/article/releases/johnson-and-johnson-s-tar-200-monotherapy-achieves-high-disease-free-survival-of-more-than-80-percent-in-bcg-unresponsive-high-risk-papillary-nmibc

‍Implication: High bladder preservation and tolerability in papillary-only patients solidifyTAR‑200’s strategic differentiation from Anktiva and Adstiladrin.